- Home
- QURE vs CLDX Comparison
QURE vs CLDX Comparison
Compare QURE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | CLDX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | QURE | CLDX |
|---|---|---|
| Price | $25.30 | $26.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $58.55 | $44.10 |
| AVG Volume (30 Days) | ★ 1.7M | 676.7K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,751,000.00 | $2,599,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142.93 | $23.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $14.40 |
| 52 Week High | $71.50 | $30.50 |
Technical Indicators
Market Signals| Indicator | QURE | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 51.31 |
| Support Level | $21.64 | $25.00 |
| Resistance Level | $25.80 | $26.96 |
| Average True Range (ATR) | 1.74 | 1.18 |
| MACD | 0.47 | 0.01 |
| Stochastic Oscillator | 53.94 | 50.15 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.